Metabolic and endocrine effects of sedative agents

Current Opinion in Critical Care

Volumn 11, Issue 4, 2005, Pages 312-317

  Mistraletti, Giovanni ^a   Donatelli, Francesco ^a   Carli, Franco ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Hormones; Metabolism; Sedative and analgesic drugs; Stress response

Indexed keywords

ANALGESIC AGENT; BENZODIAZEPINE; CATECHOLAMINE DERIVATIVE; CLONIDINE; CORTICOTROPIN; DEXMEDETOMIDINE; DOPAMINE; ETOMIDATE; FENTANYL; GROWTH HORMONE; HYDROCORTISONE; INSULIN; KETAMINE; MELATONIN; MIDAZOLAM; MORPHINE; OPIATE; PROPOFOL; THYROID HORMONE;

ANALGESIA; CIRCADIAN RHYTHM; CRITICAL ILLNESS; DRUG EFFECT; DRUG OVERDOSE; ENDOCRINE FUNCTION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTENSIVE CARE UNIT; NEUROENDOCRINOLOGY; REVIEW; RISK REDUCTION; SEDATION; SLEEP DISORDER;

ADRENERGIC ALPHA-AGONISTS; ANALGESICS; ANALGESICS, OPIOID; BENZODIAZEPINES; CATECHOLAMINES; COMBINED MODALITY THERAPY; CRITICAL CARE; ENDOCRINE SYSTEM; ETOMIDATE; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; HYPNOTICS AND SEDATIVES; INSULIN; KETAMINE; MELATONIN; METABOLISM; PAIN; PROPOFOL; THYROID HORMONES;

EID: 24344486107     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/01.ccx.0000166397.50517.1f     Document Type: Review

References (45)

1. Van den Berghe G, de Zegher F, Bouillon R. Acute and prolonged critical illness as different neuroendocrine paradigms. J Clin Endocrinol Metab 1998; 83:1827-1834.
2. Cuthbertson DP. Alterations in metabolism following injury: part II. Injury 1980; 11:175-179.
3. Timmins AC, Cotterill AM, Cwyfan Hughes SC, et al. Critical illness is associated with low circulating concentrations of insulin-like growth factors-I and II, alterations in insulin-like growth factor binding proteins, and induction of an insulin-like growth factor binding protein 3 protease. Crit Care Med 1996; 24:1460-1466.
4. Mesotten D, Delhanty PJD, Vanderhoydonc F, et al. Regulation of insulin-like growth factor binding protein-1 during protracted critical illness. J Clin Endocrinol Metab 2002; 87:5516-5523.
5. Ray DC, Macduff A, Drummond GB, et al. Endocrine measurements in survivors and non survivors from critical illness. Intensive Care Med 2002; 28:1301-1308.
6. Rydvall A, Brandstrom AK, Banga R, et al. Plasma cortisol is often decreased in patients treated in an intensive care unit. Intensive Care Med 2000; 26:545-551.
7. Rivers EP, Gaspari M, Saad GA, et al. Adrenal insufficiency in high-risk surgical ICU patients. Chest 2001; 119:889-896.
8. Voerman BJ, Van Schijndel RJMS, Groeneveld ABJ, et al. Effects of human growth hormone in critically ill non-septic patients: results from a prospective, randomized, placebo-controlled trial. Crit Care Med 1995; 23:665-673.
9. Takala J, Esko R, Nigel RW, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 341:785-792.
10. Plunkett JJ, Reeves JD, Ngo L, et al. Urine and plasma catecholamine and cortisol concentrations after myocardial revascularization: modulation by continuous sedation. Anesthesiology 1997; 86:785-796.
11. Bourne RS, Mills GH. Sleep disruption in critically ill patients: pharmacological considerations. Anaesthesia 2004; 59:374-384.
12. Frisk U, Olsson J, Nylen P, et al. Low melatonin excretion during mechanical ventilation in the intensive care unit. Clin Sci 2004; 107:47-53. Disruption of sleep in common in intensive care, and the pattern of melatonin secretion has been associated with disturbed sleep. The choice of sedatives used in intensive care does not seem to have a major influence on the melatonin level. Supplementation of melatonin might correct the hyposecretion and probably enhance the pulsatile secretion of growth hormone and prolactin.
13. Olofsson K, Alling C, Lundberg D, et al. Abolished circadian rhythm of melatonin secretion in sedated and artificially ventilated intensive care patients. Acta Anaesthesiol Scand 2004; 48:679-684.
14. Miyazaky T, Hiroyuki K, Hiroyuki K, et al. Correlation between serum melatonin circadian rhythm and intensive care unit psychosis after thoracic esophagectomy. Surgery 2003; 133:662-668.
15. Greisen J, Claus BJ, Thorbjorn G, et al. Acute pain induces insulin resistance in humans. Anesthesiology 2001; 95:578-584.
16. Akca O, Melischek M, Scheck T, et al. Postoperative pain and subcutaneous oxygen tension. Lancet 1999; 354:41-42.
17. Pilowsky I, Kaufman A. An experimental study of atypical phantom pain. Br J Psychiatry 1965; 111:1185-1187.
18. Walder B, Tramer MR. Analgesia and sedation in critically ill patients. Swiss Med Wkly 2004; 134:333-346.
19. Jacobi J, Gilles LF, Douglas BC, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002; 30:119-141.
20. Moller IW, Dinesen K, Sondergard S, et al. Effect of patient-controlled analgesia on plasma catecholamine, cortisol and glucose concentrations after cholecystectomy. Br J Anaesth 1988; 61:160-164.
21. Shapiro JM, Westphal LM, White PF, et al. Midazolam infusion for sedation in the intensive care unit: effect on adrenal function. Anesthesiology 1986; 64:394-398.
22. Kong KL, Wilatts SM, Prys-Roberts C, et al. Plasma catecholamine concentration during sedation in ventilated patients requiring intensive therapy. Intensive Care Med 1990; 16:171-174.
23. Kamijo Y, Masuda T, Nishikawa T, et al. Cardiovascular response and stress reaction to flumazenil injection in patients under infusion with midazolam. Crit Care Med 2000; 28:318-323.
24. Young C, Knudsen N, Hilton A, et al. Sedation in the intensive care unit. Crit Care Med 2000; 28:854-866.
25. Laine GA, Hossain SM, Sous RT, et al. Polyethylene glycol nephrotoxicity secondary to prolonged high-dose intravenous lorazepam. Ann Pharmacother 1995; 29:1110-1114.
26. Cammarano WB, Pittet JF, Weitz S, et al. Acute withdrawal syndrome related to the administration of analgesics and sedative medications in adult intensive care unit patients. Crit Care Med 1998; 26:676-684.
27. Shafer A. Complications of sedation with midazolam in the intensive care unit and a comparison with other sedative regimens. Crit Care Med 1998; 26:947-956.
28. Busto U, Sellers EM, Naranjo CA, et al. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med 1986; 315:854-859.
29. Beller JP, Pottecher T, Lugnier A, et al. Prolonged sedation with propofol in ICU patients: recovery and blood concentration changes during periodic interruptions in infusion. Br J Anaesth 1988; 61:583-588.
30. Walder B, Elia N, Henzi I, et al. A lack of evidence of superiority of propofol versus midazolam for sedation in mechanically ventilated critically ill patients: a qualitative and quantitative systematic review. Anesth Analg 2001; 92:975-983.
31. Izurieta R, Rabatin JT. Sedation during mechanical ventilation: a systematic review. Crit Care Med 2002; 30:2644-2648.
32. Aitkenhead AR, Pepperman ML, Willatts SM, et al. Comparison of propofol and midazolam for sedation in critically ill patients. Lancet 1989; 2:704-709.
33. McCage K, Perry C. Propofol: a review of its use in intensive care sedation of adults. CNS Drugs 2003; 17:235-272.
34. Montanini S, Pratico C, Tufano R, et al. Propofol for sedation in the intensive care unit: comparative evaluation of 1% and 2% formulations. Br J Intensive Care 1999; 9:110-114.
35. Barrientos-Vega R, Sanchez-Soria M, Morales-Garcia C, et al. Pharmacoeconomic assessment of propofol 2% used for prolonged sedation. Crit Care Med 2001; 29:317-322.
36. Cannon ML, Glazier SS, Bauman LA. Metabolic acidosis, rhabdomyolysis, and cardiovascular collapse after prolonged propofol infusion. J Neurosurg 2001; 95:1053-1056.
37. Vasile B, Rasulo F, Candiani A, et al. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med 2003; 29:1417-1425.
38. Wolf A, Weir P, Segar P, et al. Impaired fatty acid oxidation in propofol infusion syndrome. Lancet 2001; 357:606-607.
39. Cremer OL, Moons KGM, Bouman EAC, et al. Long-term propofol infusion and cardiac failure in adult head-injured patients. Lancet 2001; 357:117-118.
40. Kelly DF. Propofol infusion syndrome. J Neurosurg 2001;925-926.
41. Venn RM, Bryant A, Hall GM, et al. Effects of dexmedetomidine on adrenocortical function, ad the cardiovascular, endocrine and inflammatory responses in post-operative patients needing sedation in intensive care unit. Br J Anaesth 2001; 86:650-656.
42. Flacke JW, Bloor BC, Flacke WE, et al. Reduced narcotic requirement by clonidine with improved hemodynamic and adrenergic stability in patients undergoing coronary bypass surgery. Anesthesiology 1987; 67:11-19.
43. Belhoula M, Ciebiera JP, De La Chapelle A, et al. Clonidine premedication improves metabolic control in type 2 diabetic patients during ophthalmic surgery. Br J Anaesth 2003; 90:434-439.
44. Watt I, Ledingham IM. Mortality amongst multiple trauma patients admitted to an intensive therapy unit. Anaesthesia 1984; 39:973-981.
45. Absalom A, Pledger D, Kong A. Adrenocortical function in critically ill patients 24h after a single dose of etomidate. Anaesthesia 1999; 54:861-867.